ALKERMES | ALKS - Операционный доход





Операционный доход Изменить Дата
AbbVie USD 6.72B 1.99B 2026-06
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
ALKERMES USD -65.93M 17.65M 2026-06
Amgen USD 4.61B 777M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
J&J USD 7.48B 860M 2026-06
Malin Corporation EUR -1.1M 400K 2024-12
Merck USD 840M 2.72B 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Otsuka Holdings JPY 140.41B 22.2B 2026-06
Ovoca Bio EUR -173K 990K 2025-12
Pfizer USD 667M 4.32B 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06